• Martha Grogan, Francisco Lopez-Jimenez, Michal Cohen-Shelly, Angela Dispenzieri, Zachi I Attia, Omar F Abou Ezzedine, Grace Lin, Suraj Kapa, Daniel D Borgeson, Paul A Friedman, and Dennis H Murphree.
• Department of Cardiovascular Diseases, Mayo Clinic, Rochester, MN. Electronic address: grogan.martha@mayo.edu.
• Mayo Clin. Proc. 2021 Nov 1; 96 (11): 276827782768-2778.

ObjectiveTo develop an artificial intelligence (AI)-based tool to detect cardiac amyloidosis (CA) from a standard 12-lead electrocardiogram (ECG).MethodsWe collected 12-lead ECG data from 2541 patients with light chain or transthyretin CA seen at Mayo Clinic between 2000 and 2019. Cases were nearest neighbor matched for age and sex, with 2454 controls. A subset of 2997 (60%) cases and controls were used to train a deep neural network to predict the presence of CA with an internal validation set (n=999; 20%) and a randomly selected holdout testing set (n=999; 20%). We performed experiments using single-lead and 6-lead ECG subsets.ResultsThe area under the receiver operating characteristic curve (AUC) was 0.91 (CI, 0.90 to 0.93), with a positive predictive value for detecting either type of CA of 0.86. By use of a cutoff probability of 0.485 determined by the Youden index, 426 (84%) of the holdout patients with CA were detected by the model. Of the patients with CA and prediagnosis electrocardiographic studies, the AI model successfully predicted the presence of CA more than 6 months before the clinical diagnosis in 59%. The best single-lead model was V5 with an AUC of 0.86 and a precision of 0.78, with other single leads performing similarly. The 6-lead (bipolar leads) model had an AUC of 0.90 and a precision of 0.85.ConclusionAn AI-driven ECG model effectively detects CA and may promote early diagnosis of this life-threatening disease.Copyright © 2021 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

26 keywords...

hide…